Clinical Trials Logo

Filter by:
NCT ID: NCT00435838 Completed - HIV Infection Clinical Trials

A Study of Patient Management in HIV-1 Infected Patients Found to Have the Genetic Marker HLA-B*5701

Start date: March 2007
Phase: N/A
Study type: Observational

This is a retrospective observational study which follows on from CNA106030 (a study evaluating whether prospective genetic screening for HLA-B*5701 can reduce the incidence of hypersensitivity reactions to abacavir). This study aims to collect data on approximately 35 subjects who withdrew from CNA106030 when found to be HLA-B*5701 positive. HIV disease management and adverse event data in these subjects, where the risk/benefit ratio of treatment with abacavir may alter subsequent prescribing, will be collected

NCT ID: NCT00435656 Completed - HIV Infections Clinical Trials

Pharmacogenetics of Antiretroviral Drugs

Start date: September 2007
Phase: Phase 4
Study type: Observational

In this research project, we will study the genetic determinants that influence the pharmacokinetics of antiretroviral drugs used in the treatment of diseases caused by the HIV.

NCT ID: NCT00435539 Completed - Clinical trials for Vitreomacular Traction

A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)

Start date: February 2007
Phase: Phase 2
Study type: Interventional

A multicenter study to compare multiple doses of intravitreal microplasmin for non-surgical PVD induction for treatment of patients with vitreomacular traction.

NCT ID: NCT00435409 Completed - Breast Neoplasms Clinical Trials

A Study Of Sunitinib In Combination With Capecitabine Compared With Capecitabine In Patients With Breast Cancer

Start date: February 2007
Phase: Phase 3
Study type: Interventional

The treatment received with sunitinib plus capecitabine could delay tumor growth longer than with treatment with capecitabine alone.

NCT ID: NCT00435396 Completed - Clinical trials for Infections, Cytomegalovirus

Study to Evaluate Safety and Immunogenicity of the GSK Bio CMV Vaccine in CMV-seronegative Healthy Male Adult Subjects

Start date: February 22, 2007
Phase: Phase 1
Study type: Interventional

This will be the first time in humans (FTIH) study with the GSK Bio recombinant gB antigen to evaluate safety and immunogenicity of this CMV candidate vaccine with a proprietary GSK adjuvant system. The vaccine will be administered to young male healthy subjects at 0, 1 and 6 months. The trial will assess the safety and immunogenicity of the candidate CMV vaccine. An additional secondary objective of this trial is to identify and validate a test which will be able to differentiate between previous CMV infection and CMV vaccination. Subjects will be followed for a total of 2 years.

NCT ID: NCT00435162 Completed - Hypertension Clinical Trials

Dose Response of Valsartan on Sitting Systolic Blood Pressure in Children 6 Months - 5 Years of Age With High Blood Pressure

Start date: March 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the safety and efficacy of three doses of valsartan (0.25, 1.0, and 4.0 mg/kg) on mean sitting systolic blood pressure (MSSBP) and mean sitting diastolic blood pressure (MSDBP) in 6 months - 5 year old children with hypertension (sitting systolic blood pressure [SSBP] ≥ 95th percentile ).

NCT ID: NCT00434967 Completed - Hypertension Clinical Trials

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo

Start date: January 2007
Phase: Phase 3
Study type: Interventional

The aim is to compare the blood pressure lowering effect of the combination of candesartan cilexetil (candesartan) 32 mg and hydrochlorothiazide (HCT) 25 mg to that of candesartan 32 mg alone, HCT 25 mg alone and placebo in hypertensive adults.

NCT ID: NCT00434668 Completed - Clinical trials for Non-small Cell Lung Cancer

Evaluation of Tolerability of Adjuvant Cisplatin/Docetaxel in Completely Resected Stage IB/II Non-Small Cell Lung Cancer

TOLEDO
Start date: December 2005
Phase: Phase 2
Study type: Interventional

The aim of this study is to evaluate the tolerability (in terms of drug delivery and toxicity) of four cycles of adjuvant docetaxel plus cisplatin in patients with completely resected stage IB-II Non-Small Cell Lung Cancer. To avoid a selection bias, eligible patients will be randomised to receive cisplatin/docetaxel or cisplatin/vinorelbine.

NCT ID: NCT00434512 Completed - HIV Infections Clinical Trials

Dose-ranging Study to Evaluate the Safety & Immunogenicity of a HIV Vaccine 732461 in Healthy HIV Seronegative Volunteers

Start date: February 20, 2007
Phase: Phase 2
Study type: Interventional

GSK has constructed a new HIV immunogen comprised of conserved parts of the HIV virus (gag, pol and nef). The principal objectives of this study are to evaluate the reactogenicity and safety of this candidate vaccine with or without a GSK proprietary adjuvant system at three different doses and to evaluate the CD4+ T-cell response in terms of proportion of responders to the antigens two weeks after the second vaccination.

NCT ID: NCT00434174 Completed - Clinical trials for Non Small Cell Lung Cancer

Safety of Everolimus and Pemetrexed in Lung Cancer Patients

Start date: December 2006
Phase: Phase 1
Study type: Interventional

This study will evaluate the safety of everolimus in combination with pemetrexed when used as treatment in patients with non small cell lung cancer.